selectION, Inc.

selectION, Inc. is a biotechnology firm focused on innovative pharmaceuticals that treat autoimmune diseases and disorders related to ion channels. Their lead product, si-544, specifically targets T-cell mediated autoimmunity. Founded in 2017 and headquartered in San Diego, US, selectION, Inc.

specializes in therapeutic solutions for autoimmune conditions. The company has engaged in 2 significant deals, with its latest funding round being a Series A, raising USD 5. 06 mn on April 1, 2021, bringing the total amount raised to USD 5. 06 mn and a current company valuation of USD 27.

52 mn. selectION, Inc. focuses on developing innovative pharmaceuticals aimed at treating autoimmune diseases and disorders related to ion channels. Their primary product, si-544, is a best-in-class Kv1.

3 ion channel blocker that specifically targets T-cell mediated autoimmunity while preserving patients’ full immunocompetence. This product is designed to improve the quality of life for individuals suffering from conditions such as psoriasis vulgaris and psoriatic arthritis. Currently, selectION serves a diverse clientele which includes healthcare providers and research institutions across North America and Europe, specifically in the United States and Germany. The company’s offerings are positioned within the biotechnology sector, addressing critical therapeutic needs for patients managing autoimmune disorders.

selectION, Inc. generates revenue primarily through partnerships and clinical collaborations in the biopharmaceutical sector. The company engages in B2B transactions, collaborating with healthcare institutions and research organizations to deliver its flagship product, si-544. These partnerships typically involve structured agreements where selectION provides access to its drug development pipeline in exchange for funding or service agreements, thus establishing a collaborative platform for research and development.

Specific pricing plans for their products and services are tailored to the needs of their partners, reflecting the bespoke nature of biopharmaceutical transactions. Revenue is further supported by ongoing clinical trials and strategic partnerships that enhance their market presence within the therapeutic landscape for autoimmune diseases. selectION, Inc. is focused on expanding its product line, with plans to launch new therapeutics targeting additional autoimmune conditions in the coming years.

The company aims to penetrate new markets in Europe, particularly Germany, by 2023, leveraging recent Series A funding of USD 5. 06 mn to support these initiatives. Additionally, funds will be directed towards enhancing clinical trials and developing strategic partnerships that can further bolster its competitive position in the biopharmaceutical industry.